MEDP Q2 Deep Dive: Backlog Conversion, Lower Cancellations, and Therapeutic Mix Drive Outlook

July 22, 2025 at 14:44 PM EDT

MEDP Cover Image

Clinical research company Medpace Holdings (NASDAQ: MEDP) announced better-than-expected revenue in Q2 CY2025, with sales up 14.2% year on year to $603.3 million. The company’s full-year revenue guidance of $2.47 billion at the midpoint came in 13% above analysts’ estimates. Its GAAP profit of $3.10 per share was 3.5% above analysts’ consensus estimates.

Is now the time to buy MEDP? Find out in our full research report (it’s free).

Medpace (MEDP) Q2 CY2025 Highlights:

Revenue: $603.3 million vs analyst estimates of $542 million (14.2% year-on-year growth, 11.3% beat)
EPS (GAAP): $3.10 vs analyst estimates of $3.00 (3.5% beat)
Adjusted EBITDA: $130.5 million vs analyst estimates of $117 million (21.6% margin, 11.5% beat)
The company lifted its revenue guidance for the full year to $2.47 billion at the midpoint from $2.19 billion, a 12.8% increase
EPS (GAAP) guidance for the full year is $14.15 at the midpoint, beating analyst estimates by 11%
EBITDA guidance for the full year is $530 million at the midpoint, above analyst estimates of $473.7 million
Operating Margin: 20.9%, up from 19.9% in the same quarter last year
Organic Revenue rose 14.2% year on year, in line with the same quarter last year
Market Capitalization: $8.88 billion

StockStory’s Take

Medpace’s second quarter was marked by a strong positive market reaction, driven by a combination of higher-than-expected revenue growth and operational execution. Management credited the quarter’s outperformance to a significant decline in project cancellations, improved funding across key clients, and an increased mix of faster-executing clinical research projects, particularly in metabolic therapeutic areas. CEO August Troendle noted that the increase in award notifications and lower cancellations led to backlog conversion rates that were the highest in the past five quarters. He added, “Cancellations were down across the pipeline and awards recognized in the backlog were the highest in the past 5 quarters.”

Looking forward, Medpace’s raised annual guidance reflects management’s expectation that improved funding conditions, continued low cancellation rates, and a shift toward faster-burning studies will sustain revenue and profit momentum. The company anticipates that the elevated mix of reimbursable costs—driven by more activity in metabolic and other fast-moving therapeutic areas—will persist through the remainder of the year. CFO Kevin Brady explained that “the increase in our guidance reflects the impact of lower second quarter backlog cancellations, improved funding on several challenged programs, which we anticipate will continue through the remainder of the year and a shift in business toward faster burning therapeutic areas.”

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to several operational and market dynamics, notably the reduced rate of study cancellations and a faster pace of clinical trial activity.

Lower project cancellations: The company experienced a meaningful drop in project cancellations, which management identified as a primary driver behind both revenue growth and backlog conversion improvements. CEO August Troendle described cancellations as being “very well behaved” this quarter compared to the elevated levels seen in prior quarters.
Therapeutic mix shift: Medpace’s project mix moved further toward metabolic and other fast-executing therapeutic areas. These trials typically have a higher proportion of reimbursable costs and convert backlog to revenue more quickly, supporting the quarter’s strong financial results.
Accelerated client decision-making: The rate of client decisions increased, resulting in more awards being moved into backlog. Troendle noted that while the company’s competitive win rate was lower this quarter, the sheer volume of decisions led to a strong level of new awards.
Investigator costs rose: Higher investigator costs—payments to clinical trial sites for conducting research—were a material factor in revenue growth, as studies advanced ahead of projected schedules and required more reimbursements.
Improved funding environment: Management reported that funding challenges for clients began to stabilize, allowing more ongoing studies to receive adequate resources. This improved funding environment was cited as key to reducing cancellations and enabling more rapid project execution.

Drivers of Future Performance

Management’s outlook for the remainder of the year is shaped by trends in customer funding, project mix, and operational efficiency.

Sustained backlog conversion: The company anticipates that a continued focus on faster-burning therapeutic areas, particularly metabolic studies, will keep backlog conversion rates elevated. This is expected to accelerate near-term revenue but introduces uncertainty if the mix shifts back to slower-burning projects.
Dependence on low cancellations: The positive momentum in revenue and margin guidance depends heavily on the recent trend of lower project cancellations persisting. Management acknowledged that a reversal in this trend could negatively impact bookings and growth prospects into next year.
Hiring and productivity dynamics: To support increased project activity, Medpace expects to accelerate hiring in the second half of the year, with full-year headcount growth targeted in the mid-to-high single digits. Management also highlighted improved staff retention rates and ongoing operational productivity gains, though they cautioned that further productivity improvements may be limited.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be focused on (1) whether the trend of reduced project cancellations persists, supporting stable backlog replenishment; (2) the ongoing mix of faster-burning versus slower-burning clinical trial projects and its effect on revenue recognition; and (3) Medpace’s ability to scale operations and hiring to match increased project activity. We are also monitoring how changes in client funding and industry dynamics could influence future bookings.

Medpace currently trades at $482.97, up from $308.94 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

Trump’s April 2024 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

About Us

Laser Focus World Membership

Magazine Subscription

Newsletter Subscription

The Daily Beam

Product Watch

Bio & Life Sciences Product Watch

Laser Processing Product Watch

Get Published!

Photonics Hot List

Following the Photons: A Photonics Podcast

Social Media

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board